0
     

Report Added
Report already added
Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Drugs In Development, 2022, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pheochromocytoma - Overview
Pheochromocytoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pheochromocytoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pheochromocytoma - Companies Involved in Therapeutics Development
Advanced Accelerator Applications SA
AstraZeneca Plc
Chimerix Inc
Enterome Bioscience SA
Exelixis Inc
Gibson Oncology LLC
Ipsen SA
Jubilant DraxImage Inc
Lixte Biotechnology Holdings Inc
Merck & Co Inc
Pfizer Inc
Tarveda Therapeutics Inc
Vyriad Inc
Pheochromocytoma - Drug Profiles
211At-MABG - Drug Profile
Product Description
Mechanism Of Action
belzutifan - Drug Profile
Product Description
Mechanism Of Action
History of Events
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
History of Events
EO-2401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
iobenguane I 131 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lanreotide acetate PR - Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LMP-400 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lutetium Lu 177 dotatate - Drug Profile
Product Description
Mechanism Of Action
History of Events
olaparib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONC-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PEN-221 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sunitinib malate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Voyager-V1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Pheochromocytoma - Dormant Projects
Pheochromocytoma - Product Development Milestones
Featured News & Press Releases
Jul 27, 2021: Clinical trial of Belzutifan in pancreatic NETs and Pheo/Para
May 28, 2020: Oncoceutics to present additional data at ASCO showing clinical benefit from ONC201 for Cancer Patients
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pheochromocytoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, 2022
Pheochromocytoma - Pipeline by AstraZeneca Plc, 2022
Pheochromocytoma - Pipeline by Chimerix Inc, 2022
Pheochromocytoma - Pipeline by Enterome Bioscience SA, 2022
Pheochromocytoma - Pipeline by Exelixis Inc, 2022
Pheochromocytoma - Pipeline by Gibson Oncology LLC, 2022
Pheochromocytoma - Pipeline by Ipsen SA, 2022
Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, 2022
Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, 2022
Pheochromocytoma - Pipeline by Merck & Co Inc, 2022
Pheochromocytoma - Pipeline by Pfizer Inc, 2022
Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, 2022
Pheochromocytoma - Pipeline by Vyriad Inc, 2022
Pheochromocytoma - Dormant Projects, 2022

List of Figures
Number of Products under Development for Pheochromocytoma, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM